Investment Rating - The industry investment rating is maintained at "Overweight" [2] Core Viewpoints - The initiation of the real-world comprehensive value evaluation pilot work by the National Medical Insurance Administration is expected to enhance the clinical evaluation system for traditional Chinese medicine (TCM) [8][9][10] - The TCM sector has shown a relative performance decline compared to the broader pharmaceutical sector, with a 1.95% drop last week [4][14] - The TCM sector's current Price-to-Earnings (PE) ratio is 27.38X, reflecting a slight decrease, while the Price-to-Book (PB) ratio stands at 2.32X [6] Market Performance - The TCM index closed at 6449.62 points, down 1.95% last week, while the overall pharmaceutical sector fell by 2.2% [4][14] - The performance of individual companies within the TCM sector varied, with notable gainers including Fangsheng Pharmaceutical and Tianmu Pharmaceutical, while companies like Zhongsheng Pharmaceutical and Zhendong Pharmaceutical lagged [5][20][22] Valuation Metrics - The TCM sector's PE (ttm) is at 27.38X, down 0.54X week-on-week, with a one-year range of 24.72X to 30.26X [6] - The PB (lf) is recorded at 2.32X, also showing a slight decrease, with a one-year range of 2.17X to 2.65X [6] Supply Chain Insights - The demand for TCM materials has increased, particularly for gift-giving purposes, leading to a slight rise in the price index [7] - The overall price index for TCM materials was 237.22 points, reflecting a 0.4% increase from the previous week [7] Investment Recommendations - The report suggests focusing on three main investment themes: price governance, consumption recovery, and state-owned enterprise reform [11][12] - Specific investment targets include companies with strong R&D capabilities and unique products, as well as those less affected by centralized procurement [11][12]

Investment Rating - The industry rating is maintained at "Overweight" [6][31] Core Insights - The third quarter monetary policy meeting emphasized the execution of policies and the release of effects, acknowledging steady economic progress while focusing on insufficient domestic demand and low price levels [6][28] - The meeting highlighted the importance of ensuring that monetary policy measures effectively reach the real economy, with a focus on enhancing the transmission mechanism [6][29] - Support will be targeted towards key areas such as "small and micro enterprises" and "stabilizing foreign trade," with a flexible approach to incremental policy adjustments based on economic needs [6][29] - The banking sector is expected to see a relief in asset-side interest rate pressure, with a decline in deposit costs and narrowing interest margin drops, leading to relatively stable growth in bank performance [7][8] Summary by Sections Market Review - The banking index fell by 0.48% during the period from September 22 to September 26, 2025, underperforming the CSI 300 index by 1.55 percentage points [10] - The performance of major banks varied, with large banks, joint-stock banks, city commercial banks, and rural commercial banks showing slight declines [10] Industry and Company Dynamics - The third quarter monetary policy meeting acknowledged the need for effective execution of policies to support economic recovery, particularly in the context of weak credit demand [28][29] - Large banks are expected to play a crucial role in financing the real economy, with enhanced capital strength following previous capital injections [7][29] Investment Recommendations - The report suggests focusing on state-owned banks for their stable high dividend yield and potential valuation recovery opportunities for joint-stock and regional banks amid improving economic expectations [8][31] - Recommended banks include CITIC Bank, Jiangsu Bank, Chengdu Bank, Shanghai Rural Commercial Bank, Chongqing Rural Commercial Bank, Changshu Bank, and Suzhou Bank [8][31]

Investment Rating - The industry investment rating is maintained at "Overweight" [2][9] Core Views - The vaccine industry is currently transitioning from scale expansion to innovation-driven growth, facing short-term pain due to supply-demand imbalance and homogenized competition, but the long-term positive logic remains unchanged, driven by policy, demand, and technology [9][25] - The report emphasizes the importance of companies with high technical barriers and differentiated pipeline layouts, suggesting that these companies will have stronger product power and competitive advantages [9][25] Summary by Sections Recent Developments - Watson Bio's mRNA vaccine for herpes zoster has received clinical trial approval, marking a significant advancement as no mRNA-based herpes vaccine is currently on the market [4] - Kangtai Bio's trivalent influenza virus split vaccine application has been accepted, targeting individuals aged three and above [4] - The WHO has recommended the components for the 2026 Southern Hemisphere influenza vaccine, maintaining a consistent approach with previous recommendations [4] Market Performance - The vaccine sector has seen a decline of 3.07% recently, with a cumulative increase of 4.33% since the beginning of 2025 [5][6] - The vaccine sector's PE (ttm) is 101.64X, down 3.26X from the previous period, while the PB (lf) is 1.87X, down 0.06X [7] Investment Recommendations - The report suggests focusing on innovative vaccines and companies with strong research and development capabilities, particularly those with differentiated products and technical advantages [8][9] - Companies like CanSino and Kanghua Bio are highlighted as potential investment opportunities due to their innovative capabilities and market demand [9][25]

Investment Rating - The report maintains a "Buy" rating for the machinery industry [1] Core Views - In August, China's industrial profits saw a significant year-on-year increase of 20.4%, driven by macro policies and the recovery of equipment manufacturing [3] - The photovoltaic equipment sector experienced a decline in new installations in August, with a total of approximately 7.4GW added, down 55.3% year-on-year, but cumulative installations for the first eight months still grew by 64.7% [4] - The manufacturing PMI rose by 0.1 percentage points to 49.4 in August, indicating a slight improvement in manufacturing supply and demand [5] Summary by Sections Market Performance - Over the past 12 months, the machinery industry has outperformed the CSI 300 index, with a relative return of 35.4% [2] Key Company Performance - Notable companies in the machinery sector include Changchuan Technology, which saw a weekly increase of 49.4%, and Hongsheng Co., which increased by 35.4% [13][16] Investment Recommendations - The report suggests focusing on the general automation sector, such as Haomai Technology, and the photovoltaic processing equipment sector, including Jing Sheng Machinery and Aotwei, as they are expected to benefit from the recovery in manufacturing [5]

Investment Rating - The report maintains a "Buy" rating for the medical services industry [8] Core Views - The medical and biological sector experienced a decline of 2.20% this week, ranking 24th among 31 primary industries [2][12] - The medical services sub-sector reported a drop of 3.99%, closing at 7150.64 points [2][24] - ADC (Antibody-Drug Conjugates) remains a hot topic in China's innovative drug market, with significant overseas licensing agreements and increasing CDMO (Contract Development and Manufacturing Organization) demand [5][61] Summary by Sections Industry Performance - The medical services sector's PE (Price-to-Earnings) ratio is currently at 36.68X, down 1.52X from the previous week, while the PB (Price-to-Book) ratio is at 3.75X, down 0.15X [4][31] - The sector's performance has been mixed, with some companies like Bid Pharma (+10.0%) and Haoyuan Pharma (+7.4%) showing gains, while others like Haocen Medical (-16.5%) and Sunshine Nuohuo (-13.4%) faced significant declines [3][29] Key Developments - Heng Rui Pharma has entered an exclusive licensing agreement with Glenmark Specialty S.A. for its ADC drug, which could yield up to $1.093 billion in milestone payments [5][62] - The ADC sector has seen 9 business development transactions this year, totaling $17.272 billion, indicating strong market interest [6][63] Investment Recommendations - The report suggests focusing on high-growth areas such as ADC CDMO and weight-loss drug supply chains, with companies like WuXi AppTec and Haoyuan Pharma highlighted as key players [10][64] - It also points to potential recovery in profitability for third-party testing labs and consumer medical sectors, particularly in ophthalmology and dentistry [10][64]

Investment Rating - The industry investment rating is maintained at "Overweight" [2] Core Insights - The retail sector experienced a 4.32% decline last week, underperforming the CSI 300 index by 5.39 percentage points [4][9] - The current Price-to-Earnings (PE) ratio for the retail sector is 40.68X, down 1.85 percentage points from the previous week, with a one-year range of 27.98X to 43.58X [5][17] - The retail sales of consumer goods in August reached 39,668 billion yuan, growing by 3.4% year-on-year, with significant contributions from online channels and service consumption [6][20] Summary by Sections Industry Performance - The retail sector's index closed at 2,384.72 points, ranking 29th among Shenwan's primary industries [4][9] - The sector's absolute return over the past 12 months is 38.0%, while the relative return is 9.7% [3] Industry Valuation - The current Price-to-Book (PB) ratio is 1.96X, with a one-year range of 1.36X to 2.1X [5][18] Industry Dynamics - In August, retail sales of consumer goods grew by 3.4%, with a total of 39,668 billion yuan, and online retail sales increased by 9.6% [6][20] - The beauty and personal care segment showed a mild recovery, with retail sales reaching 34.9 billion yuan in August, up 5.1% year-on-year [21] Investment Recommendations - The report suggests focusing on high-end domestic beauty brands and tourism-related retail sectors as potential investment opportunities [7][24] - The upcoming Double Eleven shopping festival is expected to boost sales for domestic beauty brands, particularly high-end products [24][25]

Group 1 - The report highlights that the number of bond funds has steadily increased, currently accounting for approximately 30% of all public funds, with a similar scale proportion [3][14][15] - As of September 12, 2025, the number of medium- and long-term pure bond funds is 2,102, representing 53.75% of total bond funds, while short-term pure bond funds account for 9.36% [18][26] - The average duration of medium- and long-term pure bond funds has risen from 1.61 years in Q1 2023 to 3.98 years by Q2 2025, marking the highest level in nearly a decade [35][46] Group 2 - The report discusses three main methods for calculating the duration of bond funds: weighted average of major bonds, interest rate sensitivity method, and fund net value regression method [34] - The weighted average method is straightforward but suffers from data lag and may not accurately reflect the fund's characteristics due to the low proportion of major bonds disclosed [35][39] - The interest rate sensitivity method provides more accurate results but is limited by the infrequency of data disclosure, which affects its timeliness [42][46] Group 3 - The fund net value regression method is recommended for its higher frequency of data and ability to fit the bond fund's net value trends, although it faces challenges with multicollinearity among explanatory variables [48][50] - The report suggests using Lasso regression for variable selection in the regression model to enhance accuracy and stability [51] - The choice of explanatory variables is crucial, with recommendations to select indices based on government bonds, policy financial bonds, credit bonds, and innovative bonds to ensure granularity [56]

Investment Rating - The industry investment rating is maintained as "Buy" [2] Core Views - The central bank emphasizes the need to consolidate the stability of the real estate market and improve the foundational financial systems related to real estate [4] - Recent policies in major cities have positively impacted demand, with significant increases in new and second-hand housing transactions in Beijing and Shanghai, while Shenzhen experienced a slight decline [7] - The report suggests that the end of September is a critical period for real estate policies, with expectations for new supportive measures to be introduced [7] Summary by Sections Market Performance - Over the past 12 months, the real estate sector has shown a relative return of -7% and an absolute return of 26% [3] - In the last week, new housing transaction area in 30 major cities decreased by 3.8% year-on-year, but the cumulative transaction area from January to September showed a decline of only 5.1%, indicating a narrowing drop [6] Transaction Trends - In Beijing, the average daily transaction volume for second-hand homes increased by 11% year-on-year, while new homes saw a 52% increase [4] - In Shanghai, second-hand home transactions rose by 22% year-on-year, and new homes increased by 29% [5] - In Shenzhen, second-hand home transactions increased by 11%, but new home transactions fell by 23% [5] Investment Recommendations - The report recommends focusing on leading real estate companies with strong land acquisition capabilities and land reserves in core cities, such as Poly Developments [7] - It also suggests that leading intermediary firms, like Wo Ai Wo Jia, may benefit from the expected increase in second-hand home transactions and potential valuation recovery [7]

Investment Rating - The industry investment rating is maintained at "Overweight" [1][6][20] Core Views - The launch of the Tengshi N8L, a large six-seat luxury SUV, positions it as a strong competitor against models like Li Auto L8 and Aito M8, with a price range expected between 300,000 to 400,000 CNY [3][4] - The market outlook for the Tengshi N8L is optimistic due to the growing consumer demand for high-end SUVs, supported by Tengshi's advantages in new energy technology and luxury features [4][5] - The automotive industry is experiencing a significant transformation driven by the acceleration of intelligent technology and the increasing penetration of new energy vehicles, creating substantial market opportunities [6][19] Market Performance - Over the past 12 months, the automotive industry has shown a relative return of 20.0% compared to the CSI 300 index, with an absolute return of 53.8% [2][8] - As of September 26, 2025, the automotive industry PE (TTM) stands at 31.11 times, and PB (LF) at 2.84 times, indicating strong valuation metrics [8][13] Product Highlights - The Tengshi N8L features a spacious interior designed for family and business use, with dimensions of 5200mm in length, 1999mm in width, and 1820mm in height, along with a wheelbase of 3075mm [4] - The vehicle is powered by a hybrid system that includes a 2.0T engine with a maximum power output of 207 horsepower and a combined power of 762 horsepower from three electric motors [4] Competitive Analysis - The Tengshi N8L is expected to face intense competition from both traditional luxury brands and emerging new energy brands, necessitating continuous improvement in product quality, brand marketing, and service experience [4][5] - The automotive sector is witnessing a rapid increase in the penetration of intelligent components, which is expected to benefit related companies significantly [6][19] Investment Recommendations - Investors are advised to closely monitor the pre-sale and delivery of the Tengshi N8L, as positive market performance could lead to further stock price appreciation [5] - The report suggests focusing on high-quality companies in the automotive and component sectors, particularly those involved in intelligent driving and electric vehicle technologies [6][19]

——汽车行业周报（09.22~09.26） 相关研究： 1.《20250417湘财证券-汽车行业 -特朗普或将豁免进口汽车零部 件关税，看好汽车零部件板块》 2025.04.17 2.《20250526湘财证券-汽车行业 周 报 - 小米发布首款 SUV 车 型 YU7对比特斯拉ModelY科技含 量更足》2025.05.26 行业评级：增持（维持） 证券研究报告 2025 年 09 月 27 日 湘财证券研究所 行业研究 汽车行业周报 腾势 N8L 携"大六座"入局，理想 L8、问界 M8 迎来强劲对手 近十二个月行业表现 % 1 个月 3 个月 12 个月 相对收益 1.2 0.2 20.0 绝对收益 3.0 15.1 53.8 -20% 0% 20% 40% 24/10 24/12 25/02 25/04 25/06 25/08 汽车(申万) 沪深300 注：相对收益与沪深 300 相比 分析师：汪炜 证书编号：S0500525070001 Tel：(8621)50299604 Email：ww07001@xcsc.com 地址：上海市浦东新区银城路88号 中国人寿金融中心10楼 核心要点： 腾势 N8 ...